As FGF21 analogues and mimetics are currently in clinical trials for the treatment of various metabolic disorders such as metabolic syndrome‐associated steatohepatitis (MASH), this may open novel opportunities to modulate cancer metabolism [146, 147]. The gene discussed is FGF21; the disease is Other metabolic disease.